Blog
Insights on Oncology Pipelines, Clinical Trials & Competitive Intelligence
Perspectives from the Kognitic team on clinical trial forecasting, biomarker trends, competitive landscapes, and pharma pipeline analysis.
MAY 29, 2026
Why Pharma Needs Purpose-Built AI, Not General Models
Kognitic CEO Jaseem Mahmmdla explains why purpose-built AI systems deliver the precision, traceability, and clinical intelligence infrastructure pharma teams need for competitive decision-making.
MAY 28, 2026
Unlocking biomarker intelligence from clinical text: what we learned building BIOPSY
Kognitic's BIOPSY pipeline extracts structured biomarker intelligence from clinical text, outperforming general-purpose AI models and enabling accurate, traceable competitive and clinical insights.
MAY 27, 2026
Your Competitive Intelligence Cannot Come from a Chat Window
For years, the comparison was familiar. Kognitic vs. Citeline. Kognitic vs. Cortellis. Kognitic vs. GlobalData. Now the question is: Why not just use ChatGPT? It deserves a serious answer.
JUNE 24, 2025
The Evolving Therapeutic Landscape of Hematologic Malignancies
The Evolving Therapeutic Landscape of Hematologic Malignancies What’s Now and What’s Next Hematologic malignancies: multiple myeloma, leukemia and lymphoma—have long posed complex challenges in…
MAY 28, 2025
AI is Transforming Oncology Drug Development — and How Kognitic Empowers You to Stay Ahead
AI is Transforming Oncology Drug Development — and How Kognitic Empowers You to Stay Ahead The landscape of oncology drug development is undergoing a seismic shift
JANUARY 9, 2025
Neural Network Models to Predict Clinical Trial Completion
Clinical trials, a critical component of the drug development process, often face severe delays contributing to costs and inefficiencies in bringing the drug to the market. To address this problem
DECEMBER 23, 2024
Beyond CI Teams: A Strategic Intelligence Platform Guide for Pharma R&D, BD, and Biotech Leaders
Beyond CI Teams: A Strategic Intelligence Platform Guide for Pharma R&D, BD, and Biotech Leaders The reality of modern drug development is clear. Whether juggling multiple
JANUARY 22, 2024
Oncology Clinical Trials: Outlook and Emerging Trends
Print Report LinkedIn Oncology Clinical Trials: Outlook and Emerging Trials by Hunter Moody, Gayathri Devi, Aparna Jadhav Introduction Kognitic uses Artificial Intelligence/Machine Learning to…
JANUARY 18, 2024
ASH 2023 Rapid Insights: Acute Myeloid Leukemia
Print Report Conferences Dashboard LinkedIn ASH 2023 Rapid Insights: Acute Myeloid Leukemia by Hunter Moody and Gayathri Devi ASH 2023 will feature the latest updates and
NOVEMBER 8, 2023
ctDNA in Oncology: Current Landscape and Future Potential
Print Report LinkedIn Post ctDNA in Oncology: Current Landscape and Future Potential by Jyoti Pant and Hunter Moody Circulating tumor DNA (ctDNA) is a type of
OCTOBER 19, 2023
ESMO 2023 Emerging Trends: A Preview of Abstracts
Print Report ESMO Dashboard LinkedIn ESMO 2023 Emerging Trends: A Preview of Abstracts by Hunter Moody ESMO will once again showcase the latest groundbreaking therapies and
JUNE 23, 2023
Exploring Boundless Potential: AI Revolutionizes Oncology at ASCO 2023
Print Report LinkedIn Post Exploring Boundless Potential AI Revolutionizes Oncology at ASCO 2023 by Gayathri Raghupathy As a company artistically merging the realms of science and
MARCH 23, 2023
Current Landscape of Cell Therapy Clinical Trials
Print Report CURRENT LANDSCAPE OF CELL THERAPY CLINICAL TRIALS The first cell therapy (Provenge) to treat cancer got FDA approval in 2010. Following the approval of
MAY 24, 2021
COVID Vaccines, what’s new: an update on the latest clinical trials that are underway.
COVID Vaccines, what’s new: an update on the latest clinical trials that are underway with the currently administered vaccines The global pandemic posed a challenge for
FEBRUARY 23, 2021
What you must know about ADCs
This week we saw two major deals in the ADC landscape of oncology: Gilead acquired Immunomedic’s Trop2-directed Trodelvy in a $21B deal, giving the company
SEPTEMBER 12, 2020
Chadwick Boseman Leaves Behind A Cinematic Legacy and Shines Spotlight on Colorectal Cancer
We were deeply saddened to learn of Chadwick Boseman’s passing after a four year battle with colorectal cancer. Chadwick inspired and entertained millions through his portrayal
MAY 1, 2020
ACTT Trial Results Indicate Remdesivir’s Efficacy Against Covid-19
ACTT Trial Results Indicate Remdesivir’s Efficacy Against Covid-19 The National Institutes of Health released interim data from the Phase 3 ACTT trial, which explores remdesivir for
MAY 1, 2020
Covid-19 Spreads into the World of Oncology
Takeda has added a Covid-19 Expansion arm to their phase 1 trial exploring the small molecule TAK-981 in solid tumors and hematologic malignancies. As this pandemic
APRIL 30, 2020
Understanding Covid-19 Data, Phase 1: Learning About Phases
Kognitic has made it our mission to make Covid-19 clinical research publicly accessible. True accessibility not only requires data, but the knowledge necessary to interpret that
APRIL 29, 2020
Nearly 2,000 US Citizens to be Given COVID-19 Vaccine
Kognitic has made it our mission to make Covid-19 clinical research publicly accessible. True accessibility not only requires data, but the knowledge necessary to interpret that
APRIL 29, 2020
Slice & Dice the Data
The COVID-19 WORLDWIDE CLINICAL DEVELOPMENT Dashboard, powered by Kognitic, is an integrated tool which places the power to deep-dive into Covid19data in the hands of the
APRIL 27, 2020
Kognitic Makes a Splash in the Covid-19 Data Stream
Today, Kognitic released our Covid-19 dashboard which leverages machine learning to capture data from Covid-19 clinical trials in real-time. This portal integrates industry data to provide…
APRIL 27, 2020
Vaccines vs Treatment: Live Analysis of COVID-19 Trials
Today, Kognitic opens public access to our insight-driven, live dashboard to keep abreast of all the Covid-19 clinical developments! Updated daily with data sourced directly from
APRIL 26, 2020
Behind-the-Scenes Heroes of COVID-19
Behind-the-Scenes Heroes of COVID-19 Kognitic would like to take a moment to thank the researchers who are working unremittingly to find a cure for Covid-19. These
APRIL 21, 2020
Cancer Care in the Time of Covid-19
Cancer Care in the Time of Covid-19 While it seems much of our world has come to a halt since the spread of Covid-19, cancer
APRIL 21, 2020
CD-19 Antibody Making Waves at JPM2020
A next generation CD-19 mAb, tafasitamab is all the buzz at JPM2020! Incyte acquired tafasitamab from Morphosys, who had been developing the drug under the code
APRIL 21, 2020
Celebrating International Day of Women
On International Day of Women in Science. Kognitic would like to celebrate the great strides which women are making in science. At our company women account
APRIL 21, 2020
Don’t Get Blindsided by Emerging Targets
Imalumab is the only drug targeting oxMIF to reach clinical trials, but ultimately was terminated due to poor overall benefit-risk assessment. Now, OncoOne has announced that they
APRIL 21, 2020
Kognitic Launches Covid-19 Insight Series
With over 1 million globally confirmed Covid-19 cases, the promise of bringing lives back to ‘normal’ seems ambiguous. Amidst several strategies to fight against the disease,
APRIL 21, 2020
Kognitic Launches Innovative Map Feature to its Clinical Trial Intelligence Platform
Kognitic announces the launch of an innovative feature to its platform, one which allows its customers to plot the geographic location of active clinical trials into
APRIL 21, 2020
Kognitic: Stay One Step Ahead
BeiGene presented its upcoming milestones for their pipeline today at JPM20, including projected approvals and submissions for tislelizumab, zanubrutinib, and pamiparib. Why wait until the…
APRIL 21, 2020
Lynparza Gets NICE’s Stamp of Approval
The National Institute for Health and Care Excellence has recommended Lynparza for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer in adults…
APRIL 21, 2020
Real-Time Pipeline Data… Beyond the Conference Presentation
Roche presented its late stage pipeline today at JPM20, with tecentriq heading up oncology with six anticipated indications, including expansions in HCC, TNBC, bladdercancer, melanoma,…
APRIL 21, 2020
Take Time for World Cancer Day
Today is World Cancer Day, a day to reflect upon what strides we have been making toward helping the millions of patients battling cancer and focus
APRIL 21, 2020
Tepotinib vs Capmatinib: A Race for Approval
Merck KGaA’s MET inhibitor, Tepotinib, received approval in Japan for NSCLC yesterday, gaining a lead in the tight race against Capmatinib – Novartis’ MET inhibitor. The
APRIL 21, 2020
University of Penn Has Done It Again!
University of Penn refuses to stop innovating. After having introduced CAR-T to the fight against cancer, another Penn team has developed an a related technology which
JANUARY 11, 2020
Kognitic Team to Hear from Industry Leaders at JPM2020
JPM2020 is right around the corner! The Kognitic team is excited to hear from numerous industry leaders what is next for the pharma industry, including keynote
JANUARY 10, 2020
American Cancer Society Releases Facts & Figures for 2019
American Cancer Society Releases Facts & Figures for 2019 The American Cancer Society has released the cancer facts and figures for 2019. With almost 17 million
JANUARY 10, 2020
Kognitic Team Heads to JMP2020!
Kognitic is excited to be heading to JPM2020 to discuss the latest in innovative strategy for the pharma industry! Check out our website to see how
JANUARY 8, 2020
Celebrating Amgen and the Lazarex Cancer Foundation’s Support for Patient Care
We would like to celebrate Amgen’s partnership with the Lazarex Cancer Foundation, an organization which is dedicated to creating equitable access to clinical trials for all
JANUARY 8, 2020
Eli Lilly Pulls Away from Bispecific Antibodies
Eli Lilly announced that it is pulling the plug on LY3415244, the company’s only bispecific antibody currently in pipeline (see attached article). So which modalities is
JANUARY 8, 2020
Immunotherapy Combination Therapy Insights
Number of industry sponsored clinical trials in immunotherapy over the past two years. Classification of Immunotherapy and the tumors they are active in
JANUARY 8, 2020
Kognitic Honored by Healthcare Tech Outlook as a Top 10 Oncology Solution Provider for 2019!
Thank you Healthcare Tech Outlook for featuring Kognitic in the Top Ten Oncology Companies of 2019. We are thrilled to be listed alongside other innovative companies
JANUARY 8, 2020
Let’s take a look at the Emerging Transformative Therapies around Key Cancers
The number of emerging transformative therapy clinical trials are on the rise for the past few years. The therapies target multiple tumors and it’s difficult to
JANUARY 8, 2020
Lung Cancer Awareness Day
In honor of Lung Cancer Awareness Day (August 1st), we would like to call attention to assets currently in phase III for small cell lung cancer!
JANUARY 8, 2020
Opdivo Makes Waves in Colorectal Cancer
Interesting article about BMS expanding Opdivo’s colorectal cancer indication. Which companies could be impacted by this expansion? Kognitic’s platform can show you which companies have new
JANUARY 8, 2020
Targeting PD-L1: A New Front Runner for Oncology?
A recent study has found that antibodies which target PD-L1 are more effective than PD-1 inhibitors at blocking PD-1/PD-L1 signaling (see link below). PD-1 has been
AUGUST 23, 2019
Revolutionizing Oncology Landscapes
Automation and new computer technologies are revolutionizing all industrial areas. Until a few years ago, developing a new product was extremely protracted not to mention highly
Kognitic enables faster, more confident decisions
Not just more dataEvery week spent reconciling fragmented intelligence is a week your competitors are already acting on it. That is the cost of delay.